A confrontation of transplantable endocrine receptors in the prevention or treatment of metastasism in the brain, combined with cytochemistry, radiotherapy, or both； used to inhibit the protection of metabolic brain cells from cell death by celestial bodies. R is induced by cytotoxic chemotherapies and used to treat metabolic brain tumors.
The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.ANTAGONISTA DEL RECEPTOR DE LA ENDOTELINA ÚTIL EN LA PREVENCIÓN O EL TRATAMIENTO DE METÁSTASIS CEREBRAL EN COMBINACIÓN CON UN AGENTE DE QUIMIOTERAPIA CITOTÓXICO, RADIOTERAPIA O AMBOS； SU USO PARA INHIBIR PROTECCIÓN MEDIADA POR ASTROCITO DE UNA CÉLULA CEREBRAL METASTASICA DE UNA MUERTE CELULAR INDUCIDA POR QUIMIOTERAPIA CITOTÓXICA； Y SU USO PARA TRATAR UN TUMOR CEREBRAL METASTÁSICO.
